- Home
- PAX vs SLS Comparison
PAX vs SLS Comparison
Compare PAX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAX | SLS |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | PAX | SLS |
|---|---|---|
| Price | $9.54 | $8.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $14.83 | ★ $32.50 |
| AVG Volume (30 Days) | 1.5M | ★ 6.8M |
| Earning Date | 11-03-2026 | 11-16-2026 |
| Dividend Yield | ★ 6.66% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.22 | N/A |
| Revenue Next Year | $9.41 | N/A |
| P/E Ratio | $25.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.03 | $1.39 |
| 52 Week High | $17.80 | $15.88 |
Technical Indicators
Market Signals| Indicator | PAX | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 37.57 |
| Support Level | N/A | $4.09 |
| Resistance Level | $11.74 | $9.51 |
| Average True Range (ATR) | 0.40 | 1.08 |
| MACD | -0.21 | -0.25 |
| Stochastic Oscillator | 23.40 | 16.66 |
Price Performance
Historical ComparisonAbout PAX Patria Investments Limited
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.